Celgene buries the hatchet with India's Natco over generic Revlimid

Celgene ($CELG) is getting in the holiday spirit, settling its Revlimid patent fight with Indian generics maker Natco. Under the settlement, Celgene will let Natco roll out copycat versions of its $5 billion bestseller starting in 2022, as long as Natco agrees to a "volume-limit license." The license restricts the amount of capsules Natco can sell, giving Celgene some breathing room before Natco's full launch in 2026. More

Suggested Articles

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Merck CEO Ken Frazier, during a Forbes panel, called on private industry to "stabilize society" amid growing economic inequity and racial injustice.

Pharma TV advertising spiked to hit $182 million in September, even without the usually ubiquitous fall football media to play it on.